Miro J. Eigenmann
YOU?
Author Swipe
View article: P-02.04 Developing T cell bispecific antibodies with reduced-affinity anti-CD3 binders for a potent, efficacious, and low-cytokine response
P-02.04 Developing T cell bispecific antibodies with reduced-affinity anti-CD3 binders for a potent, efficacious, and low-cytokine response Open
View article: CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy Open
Effective T-cell responses not only require the engagement of T-cell receptors (TCRs; “signal 1”), but also the availability of costimulatory signals (“signal 2”). T-cell bispecific antibodies (TCBs) deliver a robust signal 1 by engaging t…
View article: OP0059 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A RANDOMISED PHASE IIIB STUDY
OP0059 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A RANDOMISED PHASE IIIB STUDY Open
View article: Supplementary Table S1 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Supplementary Table S1 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Open
Tabular representation of the experimental settings for the short- and long term experiments.
View article: Supplementary Figure S4 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Supplementary Figure S4 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Open
Shows the total-Erk time course in patient derived A677 tumors after single dose application of erlotinib or gefitinib respectively.
View article: Supplementary Figure S4 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Supplementary Figure S4 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Open
Shows the total-Erk time course in patient derived A677 tumors after single dose application of erlotinib or gefitinib respectively.
View article: Supplementary Figure S2 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Supplementary Figure S2 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Open
Graphs displaying plasma PK profile of the long term and short term experiments for erlotinib and gefitinib.
View article: Figure S5 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Figure S5 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Predicted versus observed values plots
View article: Supplementary Table S2 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Supplementary Table S2 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Open
Presents the estimated parameter values derived from the biomarker short term modeling.
View article: Data from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Data from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Open
We quantitatively compare the efficacy of two approved EGFR tyrosine kinase inhibitors, erlotinib and gefitinib, based on in vivo and in vitro data and show how a modeling approach can be used to scale from animal to humans. …
View article: Section S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Section S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Supplementary section S1 describes the compound properties of cibisatamab as well as details on data generation, model development and modeling strategy applied
View article: Supplementary Figure S3 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Supplementary Figure S3 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Open
Presents the goodness of fit plots when fitting a 1-compartmental model to the short term PK data.
View article: Supplementary Table S2 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Supplementary Table S2 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Open
Presents the estimated parameter values derived from the biomarker short term modeling.
View article: Table S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Table S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Parameter description and units
View article: Figure S2 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Figure S2 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Experimental data triplicate values with model fit
View article: Supplementary Figure S6 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Supplementary Figure S6 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Open
Displays the goodness of fit plots when fitting the PKPD model to tumor growth inhibition data in the cell line derived A431 xenografts.
View article: Figure S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Figure S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Detailed model schematic
View article: Supplementary Figure S1 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Supplementary Figure S1 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Open
Graph describing the impact of tumor volume on the derivation of the concentration to achieve tumor stasis when considering a non-linear tumor growth behavior.
View article: Supplementary Figure S3 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Supplementary Figure S3 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Open
Presents the goodness of fit plots when fitting a 1-compartmental model to the short term PK data.
View article: Supplementary Figure S5 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Supplementary Figure S5 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Open
Shows the goodness of fit plots when fitting a 1-compartmental model to the long term plasma PK data.
View article: Data from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Data from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Targeted T-cell redirection is a promising field in cancer immunotherapy. T-cell bispecific antibodies (TCB) are novel antibody constructs capable of binding simultaneously to T cells and tumor cells, allowing cross-linking and the formati…
View article: Supplementary Figure S6 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Supplementary Figure S6 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Open
Displays the goodness of fit plots when fitting the PKPD model to tumor growth inhibition data in the cell line derived A431 xenografts.
View article: Figure S4 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Figure S4 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Prediction distribution plots of MKN45 cell line
View article: Figure S2 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Figure S2 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Experimental data triplicate values with model fit
View article: Data from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Data from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Targeted T-cell redirection is a promising field in cancer immunotherapy. T-cell bispecific antibodies (TCB) are novel antibody constructs capable of binding simultaneously to T cells and tumor cells, allowing cross-linking and the formati…
View article: Table S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Table S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Parameter description and units
View article: Figure S3 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Figure S3 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Dose-response profiles over time of various cytokines and T cell markers from assays with MNK45 and CX1 cell lines
View article: Table S2 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Table S2 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Estimated parameter values
View article: Figure S5 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Figure S5 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Predicted versus observed values plots
View article: Supplementary Figure S2 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
Supplementary Figure S2 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Open
Graphs displaying plasma PK profile of the long term and short term experiments for erlotinib and gefitinib.